Adults 18 to 65, any sex, with Suicide or Psychosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Calgary Depression Rating Scale (CDRS)Primary· 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure depression, higher scores indicate greater depression (range of 0-27)
Baseline
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
18.20
± 4.65
Services as Usual (SAU; Comparison Group)
17.15
± 4.58
Mid-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
16.09
± 3.78
Services as Usual (SAU; Comparison Group)
15.39
± 4.59
Post-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
13.95
± 3.20
Services as Usual (SAU; Comparison Group)
15.83
± 5.26
Follow-up
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
13.55
± 3.59
Services as Usual (SAU; Comparison Group)
14.19
± 3.68
Positive and Negative Syndrome Scale (PANSS)Primary· 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure psychosis symptoms, higher scores indicate greater psychosis (range of 30-210)
baseline
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
82.72
± 13.58
Services as Usual (SAU; Comparison Group)
75.27
± 15.79
mid-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
77.68
± 12.64
Services as Usual (SAU; Comparison Group)
71.69
± 16.29
post-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
71.57
± 12.64
Services as Usual (SAU; Comparison Group)
76.96
± 16.92
follow-up
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
74.40
± 17.58
Services as Usual (SAU; Comparison Group)
71.09
± 13.71
Columbia Suicide Severity Rating Scale (C-SSRS)Primary· 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure suicide thoughts and behavior, higher scores indicate greater suicide thoughts and behavior (range of 0-5)
baseline
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
2.52
± 1.23
Services as Usual (SAU; Comparison Group)
1.77
± 1.56
mid-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
1.45
± 1.65
Services as Usual (SAU; Comparison Group)
1.48
± 1.34
post-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
1.09
± 1.51
Services as Usual (SAU; Comparison Group)
1.52
± 1.68
follow-up
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
1.05
± 1.50
Services as Usual (SAU; Comparison Group)
.86
± 1.19
Beck Hopelessness ScaleSecondary· 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure hopelessness, higher scores indicate greater hopelessness (range of 0-20)
baseline
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
7.04
± 5.33
Services as Usual (SAU; Comparison Group)
7.85
± 5.65
mid-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
5.67
± 4.72
Services as Usual (SAU; Comparison Group)
7.0
± 5.46
post-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
4.0
± 3.63
Services as Usual (SAU; Comparison Group)
7.26
± 5.82
follow-up
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
4.60
± 5.28
Services as Usual (SAU; Comparison Group)
6.0
± 5.97
Defeat Scale (D Scale)Secondary· 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure defeat, higher scores indicate greater defeat (range of 0-64)
baseline
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
31.24
± 15.86
Services as Usual (SAU; Comparison Group)
32.19
± 12.76
mid-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
27.57
± 14.28
Services as Usual (SAU; Comparison Group)
28.52
± 14.80
post-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
22.71
± 13.12
Services as Usual (SAU; Comparison Group)
27.61
± 13.71
follow-up
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
22.65
± 15.23
Services as Usual (SAU; Comparison Group)
27.90
± 15.05
The Entrapment ScaleSecondary· 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
A scale to measure entrapment, higher scores indicate greater entrapment (range of 0-64)
baseline
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
28.12
± 17.84
Services as Usual (SAU; Comparison Group)
22.04
± 14.96
mid-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
27.62
± 18.63
Services as Usual (SAU; Comparison Group)
23.83
± 16.34
post-treatment
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
18.33
± 15.60
Services as Usual (SAU; Comparison Group)
27.14
± 16.28
follow-up
Group
Value
95% CI
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
17.55
± 15.15
Services as Usual (SAU; Comparison Group)
24.0
± 16.46
Adverse events — posted to ClinicalTrials.gov
Time frame: between baseline assessment at 5 month assessment (follow up).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Cognitive Behavioral Suicide Prevention for Psychosis (Treatment Group)
Investigators will evaluate the feasibility and preliminary effectiveness of modified Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) in comparison to services-as-usual (SAU) in a randomized controlled trial. Investigators will recruit adult clients receiving services at a community mental health (CMH) setting who have a schizophrenia spectrum disorder and recent suicidal thoughts or behaviors within 3 months of screening (n=60). Client participants will be screened, enrolled and randomized to the CBSPp or SAU group. A 4-wave design will include quantitative assessments at baseline (T1), 1-month after baseline (T2), 3-months after baseline (T3), and 5-months after baseline (T4) with in-depth qualitative interviews at T3 for a random sample of adults in the CBSPp group (n=10). Providers (n=12) will be trained to deliver CBSPp and be assessed from T1-T3 to evaluate the implementation process, including in-depth qualitative interviews at T3.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07404787 — Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Ho
· NA
· recruiting
NCT07214233 — Youth Empowerment and Safety Intervention
· NA
· recruiting
NCT07343258 — Pilot Study on Follow-Up of (Acutely) Suicidal Individuals From the Flemish Suicide Helpline
· NA
· recruiting
NCT07523490 — Investigation on Suicide Risk Factors of Patients With Mood Disorders
· recruiting
NCT06571916 — Brief Skills for Safer Living (Brief-SfSL)
· NA
· recruiting
Other University of Michigan trials
Trials by the same sponsor.
NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation
· NA
· not yet recruiting
NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)
· NA
· not yet recruiting
NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness
· NA
· not yet recruiting
NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health
· NA
· not yet recruiting
NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults
· NA
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan
Last refreshed: 20 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05345184.